David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...
We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.
The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss ... Nordisk's stock rose about 5% on Friday. Meanwhile, shares of Hims & Hers, a a telehealth company offering compounded ...
Clinical trials have found that people who are on the prescription for a year can lose more than 10% of their body weight.
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback